Fundraising Fox
🦊/Companies
Sign in

Vaxess Technologies, Inc.

Cambridge, US · Founded 2012 · Delaware corporation · 3 known investors

Find your way into Vaxess Technologies, Inc.

864 people in our graph share verified history with the Vaxess Technologies, Inc. team — schools, employers, funds. One of them is your warm intro.

Dominic Jacquessonunlockedknows Lynda Tussey · together at University of Oxford (overlapped)
×3knows the team · via University of Oxford
knows the team · via The University of North Carolina at Chapel Hill
knows the team · via MIT Center for Polymer Microfabrication
×4knows the team · via University of California, Berkeley
×2knows the team · via University of Oklahoma
Biotech

Founders & leadership

Vaxess Technologies, Inc. was founded in 2012 by Livio Valenti, Kathryn Kosuda, and Michael Schrader.

LVLivio Valenti
Livio ValentiinCo-founder
KK
Kathryn KosudaCo-founder
MS
Michael SchraderCo-founder
MDMatthew Dirckx
Matthew DirckxinExecutiveMatthew Dirckx is Executive Officer at Vaxess Technologies, which develops microneedle and microfluidic devices for drug delivery. He has expertise in polymer-based micro-device prototyping and manufacturing, including injection molding and hot embossing, surface functionalization, microfluidic reagent formulation, and immunoassay development.
LT
Lynda TusseyinExecutiveLynda Tussey has over 20 years of experience in vaccine development and T cell immunotherapy research, including director and executive management roles, with expertise in advancing products from discovery through early clinical stages.
JSJohn Spiridigliozzi
John SpiridigliozziinExecutive
WT
Weiner TilsnerinExecutive
JK
Jonathan KlugeExecutive
RS
Rachel ShaExecutive
SH
Shuenn HoExecutive

Board

AD
Ann DeWittBoard director
PKPeter Kolchinsky
Peter Kolchinskyin𝕏Board directorManaging Partner at RA Capital

Investors · 3

Global Health Investment CorporationreportedNew York
Mission Biocapitalreported · 2 sourcesSan Francisco · $500Kvia Johannes Fruehauf · board
RA Capitalreported · 2 sourcesBostonvia Peter Kolchinsky · board

Reported raises · per SEC filings

Form D private placements

$136.9M disclosed across 10 rounds · 2016–2026

▶$57.3MraisedMar 2026 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Linda TusseyExecutive Officer
  • Kathryn KousdaExecutive Officer, Director
  • Livio ValentiExecutive Officer
  • Ann DeWittDirector
  • Fenel EloiDirector
  • Peter KolchinskyDirector
  • Rachel ShaExecutive Officer, Director
Offering amount
$83.5M
Amount sold
$57.3M
First sale
Mar 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.9MraisedSep 2025 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Matthew DirckxExecutive Officer
  • Jonathan KlugeExecutive Officer
  • Ann DeWittDirector
  • Fenel EloiDirector
  • Rachel ShaExecutive Officer, Director
  • Weiner TilsnerExecutive Officer
  • Peter KolchinskyDirector
  • Kathryn KosudaExecutive Officer, Director
  • Lynda TusseyExecutive Officer
  • John SpiridigliozziExecutive Officer
  • Livio ValentiExecutive Officer
Offering amount
$10M
Amount sold
$7.9M
First sale
Aug 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8.4MraisedFeb 2025 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ann DeWittDirector
  • Matthew DirckxExecutive Officer
  • Lynda TusseyExecutive Officer
  • John SpiridigliozziExecutive Officer
  • Weiner TilsnerExecutive Officer
  • Livio ValentiExecutive Officer
  • Peter KolchinskyDirector
  • Jonathan KlugeExecutive Officer
  • Kathryn KosudaExecutive Officer, Director
  • Rachel ShaExecutive Officer, Director
  • Fenel EloiDirector
Offering amount
$10M
Amount sold
$8.4M
First sale
Feb 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10.8MraisedMay 2024 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Lynda TusseyExecutive Officer
  • Mario BarroDirector
  • Kathryn KosudaExecutive Officer, Director
  • Matthew DirckxExecutive Officer
  • Ann DeWittDirector
  • Weiner TilsnerExecutive Officer
  • John SpiridigliozziExecutive Officer
  • Rachel ShaExecutive Officer
  • Fenel EloiDirector
  • Jonathan KlugeExecutive Officer
  • Livio ValentiExecutive Officer
Offering amount
$12M
Amount sold
$10.8M
First sale
May 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9.1MraisedJul 2023 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mario BarroDirector
  • Kathryn KosudaExecutive Officer, Director
  • Livio ValentiExecutive Officer
  • Jonathan KlugeExecutive Officer
  • Fenel EloiDirector
  • Ann DeWittDirector
  • Michael SchraderExecutive Officer, Director
  • Lynda TusseyExecutive Officer
Offering amount
$12.1M
Amount sold
$9.1M
First sale
Jul 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$35MraisedDec 2022 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kathryn KosudaExecutive Officer, Director
  • Ann DeWittDirector
  • Lynda TusseyExecutive Officer
  • Jonathan KlugeExecutive Officer
  • Michael SchraderExecutive Officer, Director
  • Mario BarroDirector
  • Fenel M. EloiDirector
  • Livio ValentiExecutive Officer
Offering amount
$35M
Amount sold
$35M
First sale
Apr 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedOct 2022 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael SchraderExecutive Officer, Director
  • Mario BarroDirector
  • Ann DeWittDirector
  • Livio ValentiExecutive Officer
  • Jonathan KlugeExecutive Officer
  • Kathryn KosudaExecutive Officer, Director
  • Lynda TusseyExecutive Officer
  • Fenel M. EloiDirector
Offering amount
$2M
Amount sold
$2M
First sale
Sep 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedMar 2021 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Livio ValentiExecutive Officer
  • Jonathan KlugeExecutive Officer
  • Ted HibbenExecutive Officer
  • Ann DeWittDirector
  • Lynda TusseyExecutive Officer
  • Michael SchraderExecutive Officer, Director
  • Johannes FruehaufDirector
  • Kathryn KosudaExecutive Officer, Director
  • Purnanand SarmaDirector
Offering amount
$2M
Amount sold
$2M
First sale
Mar 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Terrestrial Bio Raises $50M in Series C Fundingfinsmes.com · Mar 2026Vaxess Announces $9M in Funding for Microarray Drug Delivery Platformbio-itworld.com · Apr 2025Vaxess Technologies Raises $9M in Fundingfinsmes.com · Sep 2023Vaxess Announces $27M in Series B Fundingbio-itworld.com · Nov 2022Vaxess Technologies Awarded NIH Grant of up to $2.85 Million to Drive MIMIX™ Sustained Release Vaccine Patch Into a 2022 Phase 1 Human Trialbusinesswire.com · Apr 2021Vaxess Technologies Receives Grants Totaling $6 Million to Develop Microneedle Vaccines for Polio, Measles, Rubellaprnewswire.com · Mar 2017

Frequently asked questions

Who founded Vaxess Technologies, Inc.?
Vaxess Technologies, Inc. was founded by Livio Valenti, Kathryn Kosuda, Michael Schrader in 2012.
Who are Vaxess Technologies, Inc.'s investors?
Vaxess Technologies, Inc.'s investors include Global Health Investment Corporation, Mission Biocapital, RA Capital.
How much funding has Vaxess Technologies, Inc. raised?
Vaxess Technologies, Inc. has disclosed $136.9M raised across 10 rounds.
Where is Vaxess Technologies, Inc. headquartered?
Vaxess Technologies, Inc. is headquartered in Cambridge, US.